Integrated Management of Acute and Chronic Cardiovascular Disease

Similar documents
Integrated Management of Acute and Chronic Cardiovascular Disease

Integrated Management of Acute and Chronic. Coronary Artery Disease. PRELIMINARY PROGRAM From Prevention to Intervention

Integrated Management of Acute and Chronic. Coronary Artery Disease. FINAL PROGRAM From Prevention to Intervention

Integrated Management of Acute and Chronic Coronary Artery Disease

Coronary Reperfusion. & Secondary Prevention. Oberlech, Austria April 14 19, 2007 H. DARIUS K. HUBER A. M. ROSS P R O R A A ORGANIZERS:

Integrated Management of Acute and Chronic Cardiovascular Disease

Coronary Reperfusion. & Secondary Prevention FINAL PROGRAM. Oberlech, Austria April 5 10, 2008 H. DARIUS K. HUBER A. M.

Integrated Management of Acute and Chronic Cardiovascular Disease

10 th International Meeting Coronary Reperfusion. Secondary Prevention FINAL PROGRAM. Burghotel Oberlech Austria March 21 26, 2009

DEADLINE FOR ABSTRACTS

Integrated Management of Acute and Chronic Cardiovascular Disease

DECLARATION OF CONFLICT OF INTEREST

A Patient with Chest Pain and Atrial Fibrillation

Advance Programme ACUTE CARDIOVASCULAR CARE2015 EUROPEAN SOCIETY OF CARDIOLOGY

ANNUAL REPORT

Acute coronary syndromes A European viewpoint. Felicita Andreotti, MD PhD FESC Catholic University Hospital Cardiovascular Diseases - Rome, IT

XXI Congress of the Cardiology Society of Serbia (CSS) Preliminary Programme Zlatibor, October, 2017

PRELIMINARY PROGRAMME

Clinical and Economic Value of Rivaroxaban in Coronary Artery Disease

A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

PCHF. A novel course in heart failure management POSTGRADUATE COURSE IN HEART FAILURE

Thursday, December 7 th, 2017, 13:00 14:30

Antithrombotic therapy in the ACS patient with atrial fibrillation

Stable CAD, Elective Stenting and AFib

Additional Contributor: Glenn Levine (USA).

List of Workshops Workshop Title

University of Leipzig Heart Center

4:30 p.m. Jack Vogel Memorial Lecture Evolution and Revolution in the Treatment of Valvular Heart Disease Dr. Mack

Disclosure. Financial disclosure: National Advisory Board & Research Grant from Boehringer-Ingelheim

Joint Congress PAFCIC Complex PCI meeting

VIENNA HEART M AY FAILURE ADVANCE PROGRAMME. World Congress on Acute Heart Failure. Organised by the Heart Failure Association of the ESC

Scope of the Problem: DAPT and Triple Therapy after Stenting

Subsequent management and therapies

WHICH ANTITHROMBOTIC REGIMEN? Action Study Group Institut de Cardiologie - Pitié-Salpêtrière Hospital Paris, France.

Ischemic and bleeding risk stratification in NSTE ACS. Andrzej Budaj Postgraduate Medical School Grochowski Hospital, Warsaw, Poland

Program Schedule Cardiology Update in Sedona: The Heart of the Matter

The 2 nd Royal Brompton & Harefield Christmas Postgraduate Course

Controversies in Cardiac Pharmacology

Primary Percutaneous Coronary Intervention

Core Curriculum for the Cardiovascular Clinician

Program Agenda. Ottawa Heart Research Conference (OHRC): Steadying the Future of Atrial Fibrillation. Thursday, June 2 nd (Day 1)

September 14 th 16 th, 2017 Innsbruck, Austria

This educational programme has received unrestricted grants from:

2015 Preliminary Agenda

4 Global CARDIOVASCULAR EDUCATIONAL FORUM. Russia. Russian Cardiovascular Days ST PETERSBURG. cardiovascular-forum.com

COMPREHENSIVE CV DISEASE MANAGEMENT:

PRELIMINARY PROGRAM. 14:10-15:00 Session I: My Personal Experience CT/MR Chair: Herbert Frank Tulln, Austria Udo Hoffmann Boston, USA

POSTGRADUATE COURSE IN HEART FAILURE A NOVEL COURSE IN HEART FAILURE MANAGEMENT

Working Group on Thrombosis of the European Society of Cardiology

CENTER FOR CONTINUING & OUTREACH EDUCATION. 30 Bergen St. ADMC 710 Newark, NJ

DECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.

OBJECTIVES. New Twist To Old Disease: Cardiovascular Update /9/2017. Prevention Pre-operative Coronary Artery Disease

After acute coronary syndromes patients continue to have recurrent ischemic events despite revascularization and dual antiplatelet therapy

European Heart Journal 2015 doi: /eurheartj/ehv320

ARRHYTHMIAS AND DEVICE THERAPY

Westin Fort Lauderdale 400 Corporate Drive Fort Lauderdale, Florida 33334

DECLARATION OF CONFLICT OF INTEREST

MUSCULOSKELETAL ULTRASOUND COURSE - BASIC LEVEL- Graz, November 2 nd 4 th, 2016

FOCUS: Valve Medical University Innsbruck INNSBRUCK AUSTRIA SEPT ,

Acute Coronary syndrome

Non ST Elevation-ACS. Michael W. Cammarata, MD

Platelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary

2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation

Recognizing the High Risk NSTEMI Patient for Early Appropriate Therapy

Management of Cardiogenic shock. Prof. Christian JM Vrints

Practical Update in Cardiology 2017

Guideline for STEMI. Reperfusion at a PCI-Capable Hospital

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

REGISTER TODAY! February 9, Sheraton Mahwah Hotel. Program Directors 2 ND ANNUAL COMPREHENSIVE CV DISEASE MANAGEMENT:

September 5 th 7 th, 2018 Innsbruck, Austria

Cover Page. The handle holds various files of this Leiden University dissertation

Dual Antiplatelet Therapy: Time for a Paradigm Shift?

Timothy Malins, MD, FACC Governor, New York Chapter, American College of Cardiology President, New York Cardiological Society

ANNUAL REPORT. Identification. Working Group on Pulmonary Circulation and Right Ventricular Function

Tailoring adjunctive antithrombotic therapy to reperfusion strategy in STEMI

Invited Journal: Nature Medicine. Sponsors: Thermo Fisher Novocure Merck. Venue: Spanish National Cancer Research Centre CNIO Auditorium Madrid, Spain

What do the guidelines say?

KCS Congress: Impact through collaboration

Acute Coronary Syndromes

Controversies In STEMI Management

Αντιαιμοπεταλιακη αγωγη (ποια, πο τε και για πο σο)

2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease

Antithrombotic therapy in CAD patients with concomitant NAFV: why and for whom?

WHY SHOULD YOU ATTEND THIS YEAR S FORUM?

Why we need a consensus document on cardiogenic shock? ACCA Masterclass 2017

Cardio-Pulmonary Update 2013 August 9-21, Detailed Conference Agenda

PCHF A NOVEL COURSE IN HEART FAILURE MANAGEMENT POSTGRADUATE COURSE IN HEART FAILURE LONDON. January 2019 to October 2020

Asif Serajian DO FACC FSCAI

Primary and secondary prevention of sudden cardiac death in emerging economies

THURSDAY, 30 JUNE, 2016 FRIDAY, 1 JULY 2016

Ph. Gabriel Steg Disclosures

Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction the Randomized SHOCK-COOL Trial

Cindy L. Grines MD FACC FSCAI

FastTest. You ve read the book now test yourself

GRAZ TUTORIAL. Education in partnership. October 15 19, 2018 Graz/Austria. myesr.org/esor

The top 5 trials in the last year: Ischemic Heart Disease

High-sensitive troponin. Introduction. Platelet aggregation inhibition at admission

Sunday, March 22, 2015

Key recommendations on antithrombotic and lipid lowering therapy from the 2017 guidelines of the European Society of Cardiology

MUSCULOSKELETAL ULTRASOUND COURSE - BASIC LEVEL- Graz, November 2 nd 4 th, 2016

Transcription:

17 th International Meeting Integrated Management of Acute and Chronic Cardiovascular Disease www.cardio-congress.com ORGANIZERS: KURT HUBER (Austria) HARALD DARIUS (Germany) BERNARD GERSH (USA) CHRIS GRANGER (USA) OTMAR PACHINGER (Austria) MAIN TOPICS: Acute Coronary Syndromes Antiplatelet Agents Anticoagulants Atrial Fibrillation Biomarkers Case Presentations Congenital Heart Disease in Adults Coronary Artery Disease Coronary and Non-Coronary Devices Diabetes and Heart Guideline Updates Heart Failure Infections of the Heart Interventional Cardiology Lipid Lowering Strategies Prevention Structural Heart Disease Translational Medicine (Poster-Sessions) Innsbruck, Austria Austria Trend Congress Hotel January 23 26, 2016 FINAL PROGRAM

PREFACE This international meeting celebrates its 17 th anniversary. As in the past, the meeting is organized by the Association for the Promotion of Research in Arteriosclerosis, Thrombosis and Vascular Biology (ATVB), Vienna, Austria. It is patronized by the European Platelet Academy (EPA), and by the Working Group on Thrombosis of the ESC, respectively. In 2016, more than 40 international and national experts will guarantee an interesting conference with important topics illustrating the most contemporary and topical clinical research data mainly in the field of acute coronary syndromes, acute cardiac care, atrial fibrillation, heart failure and prevention (including new treatment strategies in lipid lowering, hypertension, and diabetes). A major focus will be on pharmacotherapy and devices as has been the case in prior meetings.. Master lectures and interactive clinical case discussions would extend our knowledge and enhance the practical relevance of the program. The number of attendees is limited to a maximum of 100 participants in order to stimulate intense discussions with international experts on case presentations and main topics a rare situation in our world of megacongresses. The invited experts will stay for the whole meeting and have an important impact on these discussions. The organizers will also invite the presenters of the best abstracts (a maximum of 18 abstracts will be accepted) to discuss their data with faculty members in moderated poster presentations. The best-of-translational medicine and best-of-clinical medicine posters will be awarded with 3,000 in total. This service will mainly refer to the group of young cardiologists of tomorrow. In addition, presenters of posters will have free access to the whole meeting. We would welcome your participation at this meeting. With best regards Kurt Huber (for the organizers) DEADLINE FOR ABSTRACT SUBSTITUTION January 10, 2016 (send your abstracts, A4 format, directly to kurt.huber@meduniwien.ac.at) 1

Saturday, January 23, 2016 Arrivals 19:30 Welcome Cocktail 20:00 Get-Together-Evening Sunday, January 24, 2016 09:00-10:00 Symposium 1: Therapeutic Strategies of ACS in Discussion I Joint Meeting with the WG on Thrombosis of the ESC chairs: D, Gulba (DE), H. Schühlen (DE) 09:00-09:25 The Future Role of Cangrelor and Vorapaxar (H. Darius, DE) 09:25-09:35 Case Presentation #1 (H. Alber, AT) 09:35-10:00 Thrombus Aspiration (D. Dudek, PL) 10:00-11:00 Symposium 2: Overcoming Challenges in Atrial Fibrillation (supported by Daiichi Sankyo Europe) moderator: F.W.A. Verheugt (NL) 10:00-10:40 A Deep Dive in Safety and Dose-reduction Data of the ENGAGE AF TIMI 48 Trial (R. Giugliano, US) 10:40-11:00 Practical Use of NOACS: To Whom, When and How? (C. Granger, US) 11:00-11:30 Break, Exhibition 2

Sunday, January 24, 2016 11:30-12:30 Symposium 3: Guideline Update I chairs: F. Van de Werf (BE), M. Grimm (AT) 11:30-11:55 Pericardial Disease (B. Maisch, DE) 11:55-12:05 Case Presentation #2 (A Rab, AT) 12:05-12:30 Endocarditis (B. Maisch, DE) 12:30-13:30 Lunch Break, Exhibition, Moderated Posters (moderators: J. Wojta, AT, R. De Caterina, IT) 13:30-14:30 Symposium 4: New Advances in Cardiovascular Pharmacotherapy (supported by Boehringer Ingelheim) moderator: K. Huber (AT) 13:30-14:00 Idarucizumab (Praxbind ) The First Antidote on the Market (F.W.A. Verheugt, NL) 14:00-14:30 A New Antidiabetic Agent with Impact on CV Events: Empaglifozin (T. Wascher, AT) 14:30-15:30 Symposium 5: Antithrombotic Therapy in Chronic Renal Disease chairs: J. Morais (PT), R. Welsh (CA) 14:30-14:50 Anticoagulants (R. De Caterina, IT) Antiplatelets (K. Schrör, DE) Antithrombotic Therapy for Patients with AFib on Renal Replacement Therapy (C. Granger, US) 15:30-16:00 Break, Exhibition 3

Sunday, January 24, 2016 16:00-17:30 Symposium 6: Antithrombotic therapy in ACS: An Unfolding Story (partially supported by The Medicines Company) chairs: D. Gulba (DE), F. Van de Werf (BE) 16:00-16:15 Case Presentation #3 (S. de Waha, DE) 16:15-16:35 Bivalirudin Pros and Cons (U. Zeymer, DE) 16:35-16:55 Clopidogrel, Prasugrel, or Ticagrelor: Crushed for Absorption? (C. Granger, US) 16:55-17:10 Case Presentation #4 (J. Sipötz, AT) 17:10-17:30 Duration of DAPT Which Strategy for Whom? (H. Schühlen, DE) 17:30-18:10 Symposium 7: Controversies in Interventional Cardiology Chairs: I. Lang (AT), H. Thiele (DE) 17:30-17:50 TAVI for Moderate Risk Patients Pro The Interventionalist s View (M. Haude, DE) Contra The Surgeon s View (M. Grimm, AT) 17:50-18:10 STEMI: The Pharmaco-invasive Approach Is Here to Stay Pro (F. Van de Werf, BE) Contra (P. Clemmensen, DK) 18:10-18:35 Symposium 8: Master Lecture 1 moderator: B. Gersh (US) Congential Heart Disease Update 2016! (J. Deanfield (UK)) 20:00 Faculty Dinner 4

Monday, January 25, 2016 09:00-11:05 Symposium 9: Guideline Updates II chairs: W.-M. Franz (AT), P. Clemmensen (DK) 09:00-09:25 NSTEMI (S. Kristensen, DK) 09:25-09:40 Case Presentation #5 (T. Brunner, AT) 09:40-10:00 Ventricular Arrhythmias and SCD (B. Merkely, HU) 10:00-11:00 Symposium 10: Controversial Issues in Acute Cardiovascular Care chairs: J. Mair (AT), U. Zeymer (DE) 10:00-10:10 Case Presentation #6 (H. Schühlen, DE) 10:10-10:30 Cooling or Not Cooling (I. Lang (AT) 10:30-10:40 Case Presentation #7 (R. Zimmermann, CDN) 10:40-11:00 The Use of IABP in Cardiogenic Shock (D. Zahger, IL) 11:00-11:30 Break, Exhibition 11:30-12:40 Symposium 11: Evolving Stent Technology (supported partially by Biosensors) moderator: B. Gersh (US) 11:30-11:45 Case Presentation #8 (R. Zweiker, AT) 11:45-12:05 The LEADERS FREE Trial Implications for Routine Clinical Practice? (K. Huber, AT) 12:05-12:20 Case Presentation #9 (S. Harb, AT) 12:20-12:40 Bioabsorbable Scaffolds An Update (D. Dudek, PL) 12:30-13:30 Lunch Break, Exhibition, Moderated Posters (moderators: I. Lang, AT, M. Möckel, DE) 5

Monday, January 25, 2016 13:30-14:30 Symposium 12: New Strategies in Heart Failure moderator: O. Pachinger (AT) 11:30-12:00 Seralaxin and LCZ 696 (K. Huber, AT) 12:00-12:30 Evolving and Future Approaches to the Management of Heart Failure (B. Gersh US) 14:30-15:30 Symposium 13: Biomarkers in Cardiology New Options Joint Meeting with the Acute Cardiovascular Care Association of the ESC (partially supported by ThermoFisher/B.R.A.H.M.S.) chairs: H. Schühlen (DE), P. Goldstein (FR) 14:30-14:50 AMI Diagnosis in the ED: Troponin LoD, Grey Zone, High Levels and the Role of Copeptin (M. Möckel, DE) 14:50-15:10 BNP or Nt-proBNP A View Point (J. Mair, AT)) 15:10-15:30 High-sensitive Troponin Is a 1 Hour Strategy Feasable? (C. Müller, CH) 15:30-16:00 Break, Exhibition 16:00-17:15 Symposium 14: Arrhythmias chairs: D. Zahger (IL), B. Merkely (HU) 16:00-16:25 Silent AFIB, Anticoagulation and the Role of Screening (M. Borggrefe, DE) 16:25-16:40 Case Presentation #10 (R. Zimmermann, CD) 16:40-17:00 The Leadless Pacemaker A Critical Evaluation (M. Borggrefe, DE) 17:00-17:15 Case Presentation #11 (E. Wessely, AT) 17:15-17:45 Break, Exhibition 6

Monday, January 25, 2016 17:45-18:35 Master Lectures 2&3 moderator: H. Darius (DE) 17:45-18:10 Reperfusion Injury and Cardioprotection A Long and Bumpy Road (B. Gersh, US) 18:10-18:35 Impact of New Imaging Strategies on Interventional Cardiology (J. Hill, UK) 20:00 Networking Evening 7

Tuesday, January 26, 2016 09:00-11:00 Symposium 15: Pharmacological Prevention of CAD chairs: J. Deanfield (UK), K. Schrör (DE) 09:00-09:15 Case Presentation #12 (G. Delle-Karth, AT) 09:15-09:40 What Is the Lowest Target for LDL Reduction? (H. Drexel, AT) 09:40-09:55 Case Presentation #13 (S. De Waha, DE) 09:55-10:20 How to Define Statin Intolerance (C. Granger, US) 10:20-10:35 Case Presentation #14 (U. Zeymer, DE) 10:35-11:00 How to Handle Antidiabetic Agents in CAD Patients (T. Wascher, AT) 11:00-11:30 Break, Exhibition 11:30-12:30 Symposium 14: Alirocumab: A Boost in Lipid Management? (supported by SANOFI) chairs: H. Drexel (AT), G. Delle-Karth (AT) 11:30-11:50 PCSK9 Inhibition: From Proof of Concept Into Clinical Practice (H. Drexel AT) 11:50-12:10 Cardiovascular Risk Reduction with PCSK9 Inhibition: Insight and Long-term Cardiovascular Outcomes (R. Zweiker, AT) 12:10-12:30 Accumulating Clinical Data on Alirocumab: What Are the Key Lessons? (T. Wascher, AT) 12:30-13:30 Lunch Break, Exhibition, Moderated Posters III (moderators: J. Wojta, AT, S. Kristensen, DK) 8

Tuesday, January 26, 2016 13:30-14:10 Symposium 15: Therapeutic Strategies of ACS in Discussion II chairs: P. Goldstein (FR), M. Haude (DE) 13:30-13:50 Pre-hospital Antithrombotic Therapy (S. Kristensen, DK) 13:50-14:10 The Role of Angiography With Out of Hospital Cardiac Arrest With/Without ST Elevation (H. Thiele, DE) 14:10-15:40 Symposium 16: Issues in Acute and Chronic Revascularization chairs: D. Dudek (PL), W.-M. Franz (AT) 14:10-14:30 NSTEMI Systems of Care (R. Welsh, CD) 14:30-14:50 FFR Invasive & Non-invasive: A New Gold Standard (J. Hill, UK) 14:50-15:10 Management of Multivessel Disease in Stable CAD (O. Pachinger, AT) 15:10-15:30 ACS the Mirror of Real Life: Realty of Delays (P. Goldstein, FR) 15:30-15:45 Coffee Break 15:45-16:35 Symposium 17: Master Lectures 4&5 chairs: C. Müller (CH), O. Pachinger (AT) 15:45-16:10 Prevention (J. Deanfield, UK) 16:10-16:35 Antithrombotics in the Elderly (J. Morais, PO) 16:35 Farewell K. Huber (AT) Departures 9

GENERAL INFORMATION Meeting Organization Association for the Promotion of Research in Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) Mariahilferstrasse 49, A-1060 Vienna, Austria Responsible for the Scientific Program Kurt Huber, MD, FESC, FACC Director, 3 rd Department of Medicine Cardiology & Intensive Care Medicine, Wilhelminenhospital Montleartstrasse 37, A-1160 Vienna, Austria Phone: (+43/1) 49 150-2301, Fax: (+43/1) 49 150-2309 E-mail: kurt.huber@wienkav.at or kurt.huber@meduniwien.ac.at Congress Secretariat Congress and Study Concept GesmbH Widerhoferplatz 4/3/19, A-1090 Vienna, Austria Contact: Ms. Mag. Franziska Beckmann Phone/Fax: (+43/699) 115 16917 E-mail: csconcept@chello.at Medical Exhibition and Advertising Medizinische Ausstellungs- und Werbegesellschaft Freyung 6, A-1014 Vienna, Austria Contact: Ms. Sonja Chmella Phone: (+43/1) 536 63-32, Fax: (+43/1) 535 60 16 E-mail: maw@media.co.at, www.maw.co.at Venue Austria Trend Hotel, Innsbruck Rennweg 12a, A-6020 Innsbruck, Austria Phone: (+43/512) 2115-0, Fax: (+43/512) 2115-500 E-mail: congress@austria-trend.at Congress Fee 600. /300. (reduced fee for physicians in education) 2-day attendance: 400. /200. 1-day attendance: 200. /100. Online Registration https://registration.maw.co.at/coronary16 www.cardio-congress.com 10

GENERAL INFORMATION Information for Poster Presenters You will get notion of acceptance of your abstract latest until January 20, 2016. There will be free access to the whole meeting for poster presenters. Posters (130x90 cm) should be mounted on the respective indicted day (Sunday, Monday, or Tuesday) from 9:00 AM to 7:00 PM. Poster presentation (3 min) and discussion (3 min) will take part during the indicated poster moderation sessions. The best basic and clinical research posters will be awarded. www.cardio-congress.com 11

SPONSORS (per November, 2015) AstraZeneca 12

International Faculty Martin BORGGREFE (Germany) Peter CLEMMENSEN (Denmark) Raffaele DE CATERINA (Italy) Harald DARIUS (Germany) John DEANFIELD (United Kingdom) Georg DELLE-KARTH (Wien) Suzanne DE WAHA (Germany) Heinz DREXEL (Austria) Dariusz DUDEK (Poland) Wolfgang-Michael FRANZ (Austria) Bernard GERSH (USA) Robert GIUGLIANO (USA) Patrick GOLDSTEIN (France) Chris GRANGER (USA) Michael GRIMM (Austria) Dietrich GULBA (Germany) Michael HAUDE (Germany) Jonathan HILL (United Kingdom) Kurt HUBER (Austria) Steen D. KRISTENSEN (Denmark) Irene LANG (Austria) Johannes MAIR (Austria) Bernhard MAISCH (Germany) Bela MERKELY (Hungary) Martin MÖCKEL (Germany) Joao MORAIS (Portugal) Christian MÜLLER (Switzerland) Otmar PACHINGER (Austria) Karsten SCHROER (Düsseldorf) Helmut SCHÜHLEN (Germany) Holger THIELE (Germany) Frans VAN DE WERF (Belgium) Freek VERHEUGT (The Netherlands) Thomas WASCHER (Austria) Rob WELSH (Canada) Johann WOJTA (Austria) Doron ZAHGER (Israel) Uwe ZEYMER (Germany) Rod ZIMMERMANN (Canada) Robert ZWEIKER (Graz) Austrian Faculty - Case Presenters Hannes ALBER (Innsbruck) Thomas BRUNNER (Wiener Neustadt) Stefan HARB (Graz) Anna RAB (Klagenfurt) Johann SIPPÖTZ (Wien) Wolfgang TKALEC (Linz) Emil WESSELY (Wien) Printed in Austria by: ROBIDRUCK A-1200 Vienna www.robidruck.co.at www.cardio-congress.com